Guillain Barré Syndrome News and Research

RSS

Guillain-Barré syndrome is an autoimmune disorder which results in the fast development of muscle weakness in a patient. It affects both women and men and can also impact anyone of any age although it can be more severe in the elderly.

Risk of Guillain-Barré syndrome decreases after COVID-19 vaccination

A new study suggests that low GBS incidence in vaccinated patients compared to non-vaccinated people should encourage the active propagation of vaccination against SARS-CoV-2.

15 Dec 2021

CDC study shows risk of Guillain-Barré syndrome elevated after Ad.26.COV2.S COVID vaccination

Researchers compile available data from the interim analysis of the number of cases of GBS and the risks posed by different vaccines.

8 Dec 2021

Brain injury markers associated with dysregulated immunological responses in COVID-19

Study shows that during hospitalization, patients with COVID-19 demonstrated elevated NfL and GFAP in a severity-dependant manner, as well as evidence of ongoing active brain injury 4 months later.

8 Dec 2021

Neurological complications are higher with SARS-CoV-2 infection than COVID vaccine, study finds

Research published in the journal Nature Medicine suggests a risk for neurological complications after the first shot of a COVID-19 vaccine. However, the likelihood of developing neurological complications remains far greater among people infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

31 Oct 2021

The neurological effects of COVID-19

What is the relationship between COVID-19 and the brain? A new review published in Tropical Biomedicine summarizes the key findings on how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe COVID-19 infection, disrupts brain activity and produces a range of long-term neurological disorders.

10 Oct 2021

SARS-CoV-2 infection may prompt Guillain-Barré syndrome

A new paper in Brain, published by Oxford University Press, indicates that a COVID-19 infection may prompt Guillain-Barré syndrome.

23 Sep 2021

Patient laments on not getting the COVID-19 vaccine

Saul Torres considers himself lucky to be alive after contracting COVID-19 and suffering from a rare neurological condition.

10 Aug 2021

COVID-19 symptoms in the feet

In a review paper recently uploaded to the Journal of Clinical Medicine by Jimenez-Cebrian et al. (May 19th, 2021), the clinical manifestations of COVID-19 in feet, in particular, are reviewed, finding that vascular, dermatological, and neurological symptoms have been widely reported.

6 Jun 2021

Protein could be key to blocking the most common bacterial cause of food poisoning

Washington State University researchers have discovered a protein that could be key to blocking the most common bacterial cause of human food poisoning in the United States.

30 Mar 2021

COVID-19 may alter host proteins to cause autoimmunity

To better understand the transient and chronic autoimmune symptoms caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, researchers from Memorial Sloan Kettering Cancer Center, Guizhou Medical University, and biotech company Curandis embarked on an endeavor to establish a comprehensive autoantigenome for COVID19.

23 Feb 2021

No inflammation of cerebrospinal fluid in COVID-19 patients with neurological features, study finds

Many patients with COVID-19 have shown neurological complications, leading to scientific interest in the role played by its causative pathogen, SARS-CoV-2, in brain inflammation. A new study has described the absence of neuroinflammation in cerebrospinal fluid (CSF).

14 Jan 2021

COVID-19 has been reported to trigger Guillain–Barré syndrome

Researchers at Rutgers Robert Wood Johnson Medical School have reported the first instance of COVID-19 triggering a recurrence of Guillain-Barré Syndrome - a rare disorder where the body's immune system attacks nerves and can lead to respiratory failure and death.

8 Dec 2020

SARS-CoV-2 enters the CNS via multiple routes and causes various neurological disorders

The COVID-19 pandemic has led to millions of deaths across the globe. The causative agent of this disease is the novel coronavirus, SARS-CoV-2.

3 Dec 2020

COVID-19 may trigger recurrent Guillain–Barré Syndrome episodes, a case study shows

A team of researchers at the Robert Wood Johnson Medical School, Rutgers University, USA, have investigated a case wherein a man experienced recurrent episodes of Guillain–Barré Syndrome after being infected with SARS-CoV-2.

26 Nov 2020

New clinical report on brain changes in deceased COVID-19 patients

German researchers published a report on a series of cases on post mortem findings of COVID-19 patients who succumbed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection along with neurological complications. Their study titled “Neuropathology of patients with COVID-19 in Germany: a post-mortem case series” is published in the latest issue of The Lancet Neurology.

6 Oct 2020

Developments in the search for a Zika vaccine - success in mice and a new platform for flavivirus vaccines

Researchers have vaccinated mice against the Zika virus, whilst others have discovered a new platform for flavivirus vaccines.

12 Dec 2019

The first locally transmitted cases of Zika have been confirmed in Europe

The first native cases of Zika virus have been confirmed in Europe. Experts are calling it a wake-up call as warming global temperatures could lead to more cases across the continent.

8 Nov 2019

Study: CD4+ T cells could be important mediators of protection against Zika virus

Immune cells called CD4+ T cells could be important mediators of protection against the Zika virus, according to a study published January 24 in the open-access journal PLOS Pathogens by Sujan Shresta of the La Jolla Institute for Allergy and Immunology, and colleagues.

25 Jan 2019

Doctor with Guillain Barré syndrome recovers back to normal life

Doctors do the darndest things. Take the one who walked right up to Dan Thomas, MD, at a lecture, got into the ready position, and proceeded to perform several squats as Thomas watched, puzzled.

6 Sep 2018

FDA approves first drug for treatment of adult AML patients with specific genetic mutation

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation.

20 Jul 2018